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Summary The influence of the prototype aromatase inhibitor Aminoglutethimide (AG) and its analogue
Rogletimide (RG) on peripheral aromatisation were investigated in 13 postmenopausal women with advanced
breast cancer. Seven patients received AG 1,000 mg daily plus Hydrocortisone (HC) cover and six received.RG
as dose escalation of 200 mg bd, 400 mg bd and 800 mg bd. In vivo aromatase inhibition was investigated using
the double bolus injection technique with [4-14C] oestrone ([4-4C]E1) and [6,7-3H] androstenedione ([6,7-3H]
4A) followed by a 96 h urine collection. The labelled urinary oestrogens were separated and purified by
chromatography and HPLC. Plasma oestradiol (E2) was also measured.
AG mean aromatase inhibition was 90.6% ± 1.8 s.e.m. and E2 suppression 75.7% ± 7.3 s.e.m. RG mean
aromatase inhibition was 50.6% ± 9.8 s.e.m. at 200 mg bd, 63.5% ± 5.7 s.e.m. at 400 mg bd and 73.8% ± 5.8
s.e.m. at 800mg bd. E2 suppression was 30.7% ± 9.5 s.e.m., 40.2% ± 10.3 s.e.m. and 57.6% ± 9.2 s.e.m.
respectively. These results confirm the efficacy of AG as an aromatase inhibitor. RG produced dose dependent
E2 suppression and aromatase inhibition, but even at the maximum tolerated dose of 800 mg bd had
sub-optimal aromatase inhibition and oestradiol suppression compared with AG.
Hormonal manipulation is an effective treatment modality in
30% of post-menopausal women with advanced breast
cancer (Stoll, 1981). The majority of endocrine treatments for
metastatic breast cancer are aimed at oestrogen deprivation
of the cancer cell, either by oestrogen receptor blockade as
with tamoxifen or by inhibition of peripheral oestrogen pro-
duction by the aromatase system of enzymes. Peripheral
aromatisation is the main source of post-menopausal oestro-
gens (Grodin et al., 1973). Its inhibition was first shown to be
an effective clinical treatment by (Hall et al., 1969) using
Aminoglutethimide (AG) and since by many others (Santen
et al., 1981; Harris et al., 1982). AG is still the only widely
available and used aromatase inhibitor. However at doses
greater than 500 mg a day its inhibition of cholesterol side
chain cleavage in the early steps of steroidogenesis and the
partial blockade of Ilp-, 18- and 21-hydroxylases in the
adrenal necessitates its administration in conjunction with
hydrocortisone to avoid hypoaldosteronism (Lonning &
Kvinnsland, 1988). AG has other side effects ranging from
self limiting rashes to serious bone marrow suppression.
Neuro-toxicity can be a particular problem in the elderly,
limiting its use in a group of patients ideally suited to aroma-
tase inhibition for palliating advanced disease. These problems
have encouraged the development ofnew, more specific second
generation aromatase inhibitors (Goss et al., 1986; Harris et
al., 1988; Stein et al., 1990a, 1990b; Dowsett et al., 1990).
Rogletimide (RG) is a non-steroidal analogue of AG
which during early development showed similar in vitro
aromatase potency (Foster et al., 1985). In vivo animal
studies revealed a lack of toxic metabolites and CNS effects
and volunteer/patient studies confirmed its ability to suppress
E2 (Haynes et al., 1991). RG did not inhibit cortisol produc-
tion either by interaction with cholesterol side chain cleavage
or with the 21- and 11P-hydroxylases and therefore does not
require cortisone replacement (Dowsett et al., 1991). Phar-
macokinetic data showed that RG induced its own hepatic
metabolism similar to AG (Haynes et al., 1991). These
preliminary phase I/II endocrine, pharmacokinetic and
clinical studies confirmed that the maximum tolerated dose
was 800 mg bd with moderate side effects (malaise, lethargy)
experienced by 50% of patients. They also suggested a dose
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related suppression of plasma E2 between 200 mg bd and
800 mg bd, although statistical significance was not achieved.
Aromatase suppression has been shown to be a more reliable
and accurate indicator of inhibition of oestrogen synthesis
than measuring the suppression of plasma E2 levels alone
(Jacobs et al., 1991) thus in order to elucidate if there was
any additional potential therapeutic benefit to be gained by
using 400 mg bd or 800 mg bd of RG as against 200 mg bd,
we performed further plasma E2 analysis in conjunction with
in vivo measurements of aromatase activity. To enable
accurate comparison we concomittantly measured and
analysed these parameters for AG. We did not perform a
crossover comparison of AG and RG in individual patients
because of the necessity of administering 5-6 injections to
each patient under the extended time period required to
allow adequate wash out for each drug. It was hoped that as
a result of this study we could rapidly select a suitable
therapeutic dose of RG to forward into phase III studies for
clinical comparison with other aromatase inhibitors.
Patients, materials and methods
Patients
The protocol was approved by the hospital ethical committee
and all patients gave informed consent. ARSAC clearance
was obtained for the use of radio-isotopes in patients. Thir-
teen women with advanced metastatic cancer of the breast,
suitable for second line endocrine therapy, were enrolled. All
were post-menopausal: ten spontaneous (more than 5 years
previously) two surgical and one radiotherapy ovarian abla-
tion (all >4 years previously). No systemic anticancer treat-
ment had been given within the 4 weeks prior to the first
aromatase study.
Demographic data are given in Table I.
Drugs
Arninoglutethimide Administered as 500 mg daily: 250 mg
morning and evening for a fortnight then escalated to
1,000 mg daily: 250 mgs qds. Hydrocortisone cover was em-
ployed through out, 20 mg in the morning and 10 mg at
night. No serious side effects were seen, three patients com-
plained of mild lethargy and one a characteristic but self
limiting rash.
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Table I Demographic details of trial patients
Q Index
Patient Age Wt Ht-2 ER Disease Treatment Duration
Rogletimide
EG 76 yrs 25.7 UK local, nodal Ovx, T, Deca 24 months
RB 49 29.4 UK local, bone, visceral T, Ovx 18
JL 67 20.9 +ve local T, AG, MPA, Mic, T 13
MM 63 27.3 +ve local, bone, visceral T 6
KD 35 13.9 UK local, bone, visceral Chemo, T, Ovx 4
EH 62 27.7 UK bone AG, T, 12
Mean 59 yrs 24.1 12.8 months
Aminoglutethimide
EL 80 yrs 20.5 +ve local, bone, visceral T, 8 months
RMa 53 24.1 UK local, bone, nodal T, 15
CS 71 19.5 UK bone, visceral T, 12
EM 62 21.9 UK local, bone, visceral T, Chemo 6
AS 65 34.9 -ve local, nodes T, 3
CD 64 24.8 UK bone TAD, MPA 18
ED 62 22.2 UK local, bone, visceral T, Chemo 6
Mean 65 yrs 23.9 9.7 months
a Responder, UK, unknown, T Tamoxifen, MPA medroxyprogesterone acetate, Deca Decadurabolin, TAD
Tamoxifen, Aminolglutethimide, Danazol, Mic Miconazole, Ovx Oopherectomy, Q/index Quetlets index.
Rogletimide All patients started at 200 mg bd, escalated to
400 mg bd, and finally 800 mg bd. A minimum of 4 weeks
was spent at each dose increment to ensure time for maximal
liver enzyme induction and steady state drug levels to occur.
At the end of the study patients were maintained on
400 mg bd provided there was no evidence ofdisease progres-
sion. Patient KD could not tolerate 800 mg bd because of
malaise and lethargy, patient EH had difficulty in escalating
to 800 mg bd because of severe headaches and malaise. This
appeared to settle with time.
Study protocol
Following previously published work (Jacobs et al., 1991;
Lonning et al., 1991) a double tracer bolus injection of
10yiCi [4-'4C] El and 500ftCi [6,7-3H] 4A dissolved in 54 ml
of ethanol/saline (92:8 w/w) was administered i.v. before
initiation of therapy (pre-treatment) and after a minimum of
4 weeks treatment at 250 mg qds for AG and at each dose
increment for RG. In the case of RG this necessitated three
on-treatment studies, at monthly intervals to investigate the
effect of dose escalation. Prior to the injection of isotope
blood samples were taken for endocrine analysis, the plasma
separated by centrifugation and stored at - 20°C.
Chemicals
High grade (analytical or HPLC) solvents were used and
obtained from BDH. [6,7-3H] 4A (41 Ci mmole 1) was a gift
from Dr R. Wade Ciba-Geigy Pharmaceuticals, Horsham,
Sussex. [4-'4C]EI (50-60 mCi mmole ') was obtained from
New England Nuclear (Dreiech, Germany) DEAE-Sephadex
was obtained from Pharmacia Ltd (Uppsala, Sweden).
Urine analysis
Analysis was according to previously published methodology
(Jacobs et al., 1991) which is described below in brief. An
800 ml aliquot of urine was thawed and the steroids concent-
rated on Sep-Pak C18 cartridges. Chromatography on a
DEAE 25 Sephadex column isolated the glucuronides using a
salt gradient followed by further concentration and elimina-
tion of the salt on Sep-Pak C18 cartridges.
The glucuronides were incubated and hydrolysed for 48 h
with 1 ml (144,000 units) of b glucuronidase. Following ether
extraction the unconjugated oestrogens were separated from
the androgens by three step column chromatography using
DEAE 25 Sephadex. The final solution of the pure oest-
rogens, oestrone (El), oestradiol (E2) and Oestriol (E3) took
place on a reverse phase HPLC using a Hypersil ODS 5 la
(Chrompack) 4.6 x 250 mm column with an acetonitrile/
phosphate buffer 0.05 M pH 3 mobile phase.
Liquid scintillation counting
A Packard tricarb 1990CA liquid scintillation beta counter
with automatic Quench calibration was used to count 3H and
14C oestrogen and androgen peaks in all samples. Sample
aliquots were counted in 10ml plastic vials with Emulsifier
Gold XR scintillation fluid (Packard) and expressed as
D.P.M. The counting programme was optimised to eliminate
channel crossover, which was 0.2%-0.4% for 3H in the 14C
channel. There was no 14C to 3H cross over.
Endocrine assay
Serum levels of E2, were measured according to previously
described methodology (Dowsett et al., 1987). All samples
from each patient were analysed in the same batch.
Calculations
In vivo aromatisation was calculated using the formula:
% Aromatisation
- (3H:14C) urine
x 100 (3H '4C) injection
The percentage aromatisation was calculated individually for
each urinary oestrogen El, E2 and E3 and a mean value of
these was then taken to represent the overall percentage
aromatisation. E2 peaks were often eliminated or too low to
analyse accurately in the on treatment samples so only El
and E3 values were used. Percentage inhibition was cal-
culated using the following formula:
% Inhibition= lo_ -% Aromatisation on treatment x 100 % Aromatisation pre treatment
Isotopic ratios
The E3:EI ratio was calculated using the total [14C] and
[3H] counts (DPM) obtained from the urinary oestrogen
peaks after HPLC purification and separation. Any shift in
oestrogen metabolism and consequent urinary oestrogen
secretion will be reflected in change of the ratio.
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Statistical method
Multiple comparisons were made using the Friedman test
(non-parametric, two-way analysis of variants). Comparisons
between the two drugs were made using the Wilcoxon two
sample statistic. All P-values are expressed as two tailed.
Results
Plasma E2 suppression (mean % ± s.e.m.) is shown in Figure
1 and 2 for AG and RG respectively. The individual patient
data is in Tables III and V respectively. For AG the mean E2
suppression was 75.7% ± 7.3 s.e.m. For RG E2 suppression
was dose dependent: 30.6% ± 9.5 s.e.m. at 200 mg bd,
40.1% ± 10.3 s.e.m. at 400mgbd and 57.6% s.e.m. ± 9.2 at
800 mg bd. Statistical significance was achieved (P-value
<0.01 Friedman) but because of the limited number of
observations it was not possible to do paired analyses at
different doses. The difference in E2 suppression between AG
and RG 800 mg bd was not statistically significant (P-value
>0.05 Wilcoxon).
The mean (E3 + El) % aromatisation values and their %
inhibition are shown individually for each patient for AG
and RG in Tables II and IV respectively. The mean ± s.e.m.
% inhibition is displayed in Figures 1 and 2 respectively.
Patients treated with AG show a high level of aromatase
inhibition: 90.6% ± 1.8 s.e.m. The patients treated with RG
demonstrated a dose response relationship for aromatase
inhibition: rising from 50.6% ± 9.8 s.e.m. at 200 mg bd to a
maximal suppression of 73.8% ± s.e.m. at 800 mg bd. Statis-
tical significance was achieved (P-value <0.025 Friedman)
but it was not possible to demonstrate any further
significance between doses because of limited numbers of
observations. Patient RB had the highest aromatase inhibi-
tion (90%) on treatment with RG. This was seen at
200 mg bd of RG with slight variations at 400 mg bd (75.6%)
and 800 mg bd (86%). Patient EH exhibited a higher inhibi-
tion rate at 400 mg bd than 800 mg bd, the reason for this is
unclear. RG aromatase inhibition rates showed wide inter-
patient variation at 200 mg bd (14.7-89.9%) and 400 mg bd
(47.7-75.7%). Only at the 800 mg bd dose did the range fall
(71.1-86.6%) corresponding to the narrower range seen with
AG (84.6-97.8%). There was no correlation in the degree of
aromatase inhibition to the magnitude of the pretreatment
aromatase value for either RG or AG. AG caused
significantly better aromatase inhibition than RG 800 mg bd
(P<0.01 Wilcoxon).
On treatment with both AG and RG there was a consis-
tent increase in the [4-14C] E3:Ej ratios for each individual
(Table VI). Figure 3 shows the individual patient ratio in-
creases on a log scale (used for clarity as many of the data
points were superimposed). Similar individual increases were
seen in the [6,7 3H] E3:Ej ratios (not shown) except for three
individuals, two on AG and one on RG, who failed to match
their [4-14C] E3:Ej ratios, having a negative value. This sub-
stantially lowered the median [6,7 3H] E3:E1 values. For AG
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Figure 2 Mean (±s.e.m.) % inhibition of aromatase and sup-
pression of oestradiol by Rogletimide.
Table II Percentage inhibition of aromatase for Aminoglutethimide
% Aromatisation
Pre On % Inhibition
RM 1.42 0.08 89.9%
EM 1.24 0.12 97.8%
AS 1.34 0.03 94.1%
EL 1.54 0.24 92.4%
CS 0.98 0.10 84.6%
CD 2.70 0.20 84.8%
ED 2.49 0.38 90.5%
Mean 90.56% ± 1.8 s.e.m.
Table III Percentage inhibition of oestradiol for
Aminoglutethimide
Oestradiol
Pre On % Inhibition
RM 30.6 4.5 85.3%
EM 16.60 2.8 83.1%
AS 14.4 4.7 67.4%
EL 34.0 22.0 35.2%
CS 37.7 6.4 83.0%
CD 46.0 4.1 91.1%
ED 34.4 5.5 94.0%
Mean 75.7% ± 7.3 s.e.m.
and RG 800 mg bd on-treatment the median increase in the
[4-14C] E3:Ej ratio was 213% (range 45-1584%) and 212%
(93-1085%) and in the [6,7 3H] E3:Ej ratio 63% (- 79-
1129%) and 122% (- 29-1463%) respectively. For RG the
ratio increase was dose related. There was a wide interpatient
variation in the on-treatment and pre-treatment ratios for
both AG and RG. For neither treatments was there a cor-
relation between initial ratio value and the magnitude of
increase.
In small studies analysis ofpatient response is not possible
but merits comment. Patients were formally staged at the
start of the study and at 3 months for AG or completion of
the study for RG. There was one responder (UICC criteria)
in the AG group. It was encouraging to note the prolonged
disease stable treatment periods with RG (21 months and 18
months, patient EG and RB respectively), in view of its
suboptimal E2 suppression and aromatase inhibition, in a
group of patients with advanced breast cancer and limited
life expectancy. Toxicity necessitating dose reduction was
experienced by only one patient (KD) and this was with RG
800 mg bd. No long term toxicity has been noted.
Discussion
Any variations in E2 suppression and aromatase inhibition
between AG and RG are difficult to explain in terms of
Aminoglutethimide
Figure 1 Mean (±s.e.m.) % inhibition of aromatase and sup-
pression of oestradiol by Aminoglutethimide.
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Table IV Percentage inhibition of aromatase for rogletimide
Pre 200mg bd % inhibition 400mgbd % inhibition 800mg bd % inhibition
EG 2.91 1.52 47.7% 0.71 75.8% 0.47 84.0%
JL 0.68 0.58 14.7% 0.36 47.7% 0.20 71.1%
MM 1.13 0.51 55.0% 0.35 69.1% 0.30 73.2%
RB 2.93 0.30 89.9% 0.71 75.6% 0.39 86.6%
EH 1.29 0.74 42.6% 0.41 68.2% 0.61 53.8%
KD 0.43 0.20 53.4% 0.24 44.0% N/A
Mean 50.6% ± 9.8 s.e.m. 63.5% ± 5.7 s.e.m. 73.8% ± 5.8 s.e.m.
Table V Percentage inhibition of oestradiol for rogletimide
Pre 200mg bd % inhibition 400mg bd % inhibition 800mgbd % inhibition
EG 10.0 9.1 10.0% 7.7 20.0% 7.1 23.0%
JL 8.8 5.3 39.7% 7.7 12.5% 5.0 44.2%
MM 42.0 32.0 23.9% 14.0 66.7% 6.5 84.5%
RB 42.0 18.0 58.2% 19.0 55.8% 9.3 77.9%
EH 13.0 15.0 0% 7.3 44.9% 5.9 61.5%
KD 12.0 5.9 51.9% 5.6 54.4% N/A
Mean 30.7% ± 9.5 s.e.m. 40.2% ± 10.3 s.e.m. 57.6% ± 9.2 s.e.m.
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Figure 3 Individual patient ratios of (4- 4C) E3:Ej with Amino-
glutethimide (AG) and Rogletimide (RG).
ciminating between different drug schedule influences on oes-
trogen suppression (Lonning et al., 1991). The isotopic tracer
studies showed a maximal aromatase inhibition of 91% for
AG 1,000 mg daily. This value is lower than the 98%
previously reported (Santen et al., 1978) but used different
methodology which may allow more accurate quantification
of aromatase conversion rates (Jacobs et al., 1991). It corres-
ponds well to the maximal aromatase inhibition rates seen
with other novel aromatase inhibitors we have investigated in
this manner: CGS 16949A 2 mgbd (Lonning et al., 1991)
and 4-hydroxyandrostenedione (4-OHA) 500 mg intramus-
cularly fortnightly (Jones et al., 1992), confirming the
usefulness of AG for treating postmenopausal breast cancer.
It has yet to be demonstrated that the degree of aromatase
inhibition correlates with clinical efficacy and it will be of
interest to discover whether 4-OHA and CGS 16949A can
match the clinical successes of AG.
In comparison RG 800 mgbd achieved only 74% arom-
t atase inhibition. This further suggests that the difference in
plasma E2 suppression between AG and RG reflects a true
difference in pharmacological activity. RG shows a wide
variation in the degree of aromatase inhibition at the lower
patient selection, or previous treatments, as all demographic
parameters were similar.
The pre-treatment aromatase values and plasma E2 levels
for all patients fell within previously described ranges (Santen
et al., 1978; Jacobs et al., 1992). The percentage E2 suppres-
sion for RG is consistent with previous work (Dowsett et al.,
1991; Haynes et al., 1991). The difference in E2 suppression
between the two drugs did not achieve statistical significance.
This may be the result of small patient numbers or assay
limited sensitivity making individual values uncertain.
Aromatase inhibitors suppress the already low post-
menopausal plasma E2 levels close to assay sensitivity limits
which may be relevant in concealing further suppression. The
lowest E2 levels seen for AG (2.8 pmol 1-') are at the limit of
assay sensitivity. Those for RG (5.0 pmol 1') were not. This
supports the difference between RG and AG in E2 suppres-
sion as being real. The degree of E2 suppression by RG is
comparable to that seen with the other aromatase inhibitors
currently under investigation (Dowsett et al., 1989, 1990). In
this study AG E2 suppression is at the top end of that
previously reported (Harris et al., 1982; Santen et al., 1978,
1982; Vermeulan et al., 1983). In vivo tracer measurements of
aromatase activity are a more sensitive means of dis-
Table VI (4-14C) E3:El ratios for aminoglutethimide and
rogletimide
Aminoglutethimide
Pre On °/o Increase
RM 1.5 4.7 213
JL 1.1 2.2 118
AS 0.6 1.1 80
EL 0.4 6.4 1584
CS 8.5 28.0 229
CD 10.7 33.0 208
ED 9.7 14.1 45.4
Median 213%
Rogletimide
Pre On % Increase
EG 0.4 1.3 237
EM 0.6 1.5 131
MM 1.7 3.6 93
RB 7.0 23.8 223
EH 0.4 5.0 1085
KD 1.0 3.2 199
Median 212%
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doses of 200 mg bd and 400 mg bd. Only at 800 mg bd does
the large interpatient range narrow, as the degree of
aromatase inhibition becomes more uniform, reflecting a
more effective dosing schedule for the majority of patients.
The reason for RGs' inferior aromatase inhibition is not
clear but may be two-fold. (i) Poor tissue/plasma concentra-
tions. Early work demonstrated that RG oral bioavailability,
like AG, was excellent and that doses of 500 mg bd were
probably supramaximal for maintaining serum levels of RG
above the 2,tg ml-' threshold required for effective E2 supp-
ression (Haynes et al., 1991). However unpublished data
from a previous study (Dowsett et al., 1991) suggested that
even at 800 mg bd, plasma RG trough levels were con-
sistently below the required therapeutic threshold in 55% of
patients. This contradiction may be the result of RG induc-
ing its own metabolism similar to AG, induction only being
detectable on more prolonged dosing schedules than
previously studied i.e. 2 weeks compared with previous 5
days. (ii) In the early stages of RG development it was
chosen from a series of analogues (Leung et al., 1987) (many
of whom had better in vitro aromatase inhibitory potential)
because of its long half life and inactive, non-toxic
metabolites. Consequently an adequate in vitro potency com-
parable to that of AG has not translated as well to the
clinical in vivo setting. Toxicity limits dose escalating RG any
further but one could assume that the dose/aromatase inhibi-
tion relationship would be maintained at higher doses of RG.
During this study it was noted that the E3:El isotope
ratios in the urine changed in the on treatment situation for
both AG and RG. This had not been noted in our previous
in-vivo work on CGS 16949A (Lonning et al., 1991) and
4-OHA (Jones et al., 1992). Recent work has suggested that
AG may have a dual mechanism of action in oestrogen
suppression: (i) direct aromatase inhibition, (ii) stimulation of
oestrogen metabolism consequent upon hepatic microsomal
enzyme induction, increasing plasma ElS clearance and
decreasing the ElS/El and ElS/E2 ratios (Lonning et al.,
1987, 1989b). The mechanism by which this occurs is stimula-
tion of the 16 a hydroxylase enzyme (Lonning & Skulstad,
1989) which converts oestrogens to E3. Any alteration in the
direction of oestrogen metabolism i.e. an increase towards E3
production and urinary excretion with a fall in that of El
(Lonning et al., 1987) will be reflected in the change of
oestrogen ratios. The change in oestrogen ratios is unlikely to
be an analytical artifact: (i) we have not seen this
phenomenon with any other aromatase inhibitors studied in
this manner. (ii) El and E3 losses are probably similar
through out the purification and separation stages of our
analysis as both steroids unlike the catechol (2-OH) oest-
rogens are known to be chemically stable and do not
undergo oxidative degradation. If a selective analytical loss
ofeither of these oestrogens accounted for the ratio change it
would be seen in all analysis not just those performed on RG
and AG. If plasma ElS is quantitively a more important
source of unconjugated oestrogens than androstendione in
the postmenopausal women and a potential source of oest-
radiol in breast tumours (Santner et al., 1986), reducing the
circulating storage pool of ElS may give AG important
clinical advantages over other more specific aromatase
inhibitors (Lonning et al., 1989a). As an AG analogue, RG
would be expected to have similar properties. This hypothesis
is indirectly supported by the comparable changes seen in the
14C E3:E1 isotope ratios on RG and AG treatment. 14C
E3:E1 ratio reversal similar to AG was seen at 800 mg bd of
RG, indicating that comparable hepatic enzyme induction
may be achieved at this dose of RG, even if aromatase
inhibition is not. The wide interpatient variations in pre and
on-treatment E3:E1 isotope ratios for both AG and RG is
the result of unknown and known factors influencing hepatic
enzyme function, e.g. diet, alcohol, drugs thyroid hormones.
The differences seen between the 3H and 14C E3:E1 ratios in
three patients in the on-treatment situation is difficult to
explain. If, as the above results suggest, liver microsomal
enzyme induction on RG is comparable to AG, then RG's
suboptimal E2 suppression may be totally accounted for by
inferior aromatase inhibition.
The difficulties of relying only on endocrine parameters for
aromatase inhibitor assessment is underlined in the work
presented here, for although the degree of E2 suppression for
RG is lower than AG, which is consistent with its lower
aromatase inhibition rates, it was not statistically significant.
Until we can find or refute a link between oestrogen suppres-
sion and tumour response we can persue and investigate only
those aromatase inhibitors deemed most 'effective phar-
macologically by full aromatase evaluation.
Conclusion
At the maximum tolerated dose of 800 mg bd, RG achieves
inferior E2 suppression and aromatase inhibition, compared
with its parent compound AG. Whether this is the result of
inadequate tissue/plasma drug concentration or poor arom-
atase inhibitory potency is of no clinical relevance as further
dose escalation of RG is limited by toxicity. It is difficult to
envisage a role for RG in the management of advanced
breast cancer in view of newer, more pharmacologically
effective aromatase inhibitors with minimal toxicity, now
being developed. In vivo aromatisation measurements per-
formed in conjunction with plasma oestrogen analysis creates
a powerful tool for evaluating the optimal therapeutic dose
and potential clinical efficacy of any new aromatase
inhibitors in small groups of patients. Early evaluation em-
ploying these methods will select out aromatase inhibitors
with low therapeutic potential reducing the need for multiple
large scale clinical trials to assess clinical potential.
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